Peter Choyke

Senior Investigator

National Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (34)

Year:

2026

Year:

2026

Year:

2026

Somatic mutation profiling is central to cancer diagnosis and treatment selection. However, most studies focus on individual actionable mutations, overlooking the broader mutational context that shapes tumor evolution and treatment response. Here, we introduce OncoBERT, a language model that learns contextual representations of somatic mutations from large-scale clinical sequencing data spanning >210,000 patients, 113 cancer types and 20 institutions. OncoBERT uncovers robust patient-specific mutational subtypes across diverse cohorts and targeted sequencing panels, revealing clinically meaningful mutation patterns that are associated with differential response to chemotherapy, targeted therapies, and immunotherapy. Importantly, integrating OncoBERT’s contextual representations with clinically approved biomarkers of immunotherapy response, such as tumor mutational burden (TMB) and microsatellite instability (MSI), significantly improved prediction of clinical benefit. By further incorporating matched tumor transcriptomic profiles, we linked OncoBERT-defined mutational subtypes to distinct cancer hallmark programs and tumor microenvironment states. Together, OncoBERT provides a scalable framework for deciphering somatic mutational landscapes, enabling improved patient stratification and advancing precision oncology.

Year:

2026

Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective cancer therapy based on a targeted monoclonal antibody conjugated to phthalocyanine-based photoabsorber, IRDye700DX (IR700). Following injection, near-infrared light activates the conjugate causing direct cytotoxicity and immunogenic cell death. The high selectivity of NIR-PIT is traditionally based on the binding of a monoclonal antibody to its target thus bringing the photoabsorber, IR700, in close proximity to the cell membrane at the time of light exposure. However, other targeting moieties can be used and in the current study, interleukin-15 (IL15) is conjugated with IR700 to enable NIR-PIT. IL15-IR700 quickly bound to the cellular membrane of MC38 HIL15Rα cells that are transfected with human IL15 receptor alpha. NIR-PIT induced characteristic morphological changes accompanied by a significant decrease of cellular viability. Intratumoral injection of IL15-IR700 resulted in longer retention of the conjugate in the tumor compared to the intravenous injection. NIR-PIT with intratumoral IL15-IR700 significantly suppressed tumor growth, induced necrosis-like changes in tumor tissue, and stimulated host immune response. This study revealed that cytokine-based NIR-PIT is a potential therapeutic strategy for treating solid cancer.

Year:

2025

Background/Objectives: 89Zr-oxine is an ex vivo cell labeling agent that enables cells to be tracked in vivo by positron emission tomography (PET) over a period of up to two weeks. To better understand where 89Zr-oxine binds within cellular components, factors affecting labeling and intracellular distribution of 89Zr were examined. Methods: Mouse primary T cells, natural killer cells, dendritic cells, and monocytes, and cell lines EL4 (mouse lymphoma), DC2.4 (mouse dendritic cell), Kit225K6 (human T cell leukemia) and MC38 (mouse colon adenocarcinoma) were labeled with 89Zr-oxine or 111In-oxine and protein binding within the cellular compartments, the labeling thresholds, and radioactivity retention were subsequently determined. Results: Cell incorporation of 89Zr-oxine (27.8–71.8 kBq/106 cells) positively correlated with cellular size and protein mass. Most (>97%) 89Zr was protein-bound and primarily localized in the cytoplasm, membrane, and nuclear fractions (>81%) with distribution patterns varying by cell type. By contrast, 111In-oxine showed lower protein-binding activity of approximately 59–65%, with 62–65% of 111In localized in the cytoplasm. Autoradiography of electrophoresed subcellular fractionated cell samples indicated stable binding by 89Zr-oxine to proteins in all subcellular fractions but unstable protein binding by 111In. Saturation studies showed that 89Zr-oxine labeling was saturable, and further labeling reduced cellular retention. Biodistribution of dendritic cells labeled with either 89Zr-oxine or 111In-oxine indicated greater retention of 89Zr in the labeled cells in vivo than 111In. Conclusions: 89Zr-oxine stably binds many intracellular proteins and shows much higher and more stable protein binding than 111In-oxine. Intracellular protein binding of 89Zr accounts for the ability of 89Zr-oxine labeling to successfully track cells in vivo long-term on PET.

Year:

2025

Background: Prostate cancer management optimally requires non-invasive, objective, quantitative, accurate evaluation of prostate tumors. The current research applies visual inspection and quantitative approaches, such as artificial intelligence (AI) based on deep learning (DL), to evaluate MRI. Recently, a different spectral/statistical approach has been used to successfully evaluate spatially registered biparametric MRIs for prostate cancer. This study aimed to further assess and improve the spectral/statistical approach through benchmarking and combination with AI. Methods: A zonal-aware self-supervised mesh network (Z-SSMNet) was applied to the same 42-patient cohort from previous spectral/statistical studies. Using the probability of clinical significance of prostate cancer (PCsPCa) and a detection map, the affiliated tumor volume, eccentricity was computed for each patient. Linear and logistic regression were applied to the International Society of Urological Pathology (ISUP) grade and PCsPCa, respectively. The R, p-value, and area under the curve (AUROC) from the Z-SSMNet output were computed. The Z-SSMNet output was combined with the spectral/statistical output for multiple-variate regression. Results: The R (p-value)–AUROC [95% confidence interval] from the Z-SSMNet algorithm relating ISUP to PCsPCa is 0.298 (0.06), 0.50 [0.08–1.0]; relating it to the average blob volume, it is 0.51 (0.0005), 0.37 [0.0–0.91]; relating it to total tumor volume, it is 0.36 (0.02), 0.50 [0.0–1.0]. The R (p-value)–AUROC computations showed a much poorer correlation for eccentricity derived from the Z-SSMNet detection map. Overall, DL/AI showed poorer performance relative to the spectral/statistical approaches from previous studies. Multi-variable regression fitted AI average blob size and SCR results at a level of R = 0.70 (0.000003), significantly higher than the results for the univariate regression fits for AI and spectral/statistical approaches alone. Conclusions: The spectral/statistical approaches performed well relative to Z-SSMNet. Combining Z-SSMNet with spectral/statistical approaches significantly enhanced tumor grade prediction, possibly providing an alternative to current prostate tumor assessment.

Year:

2025

Background/Objectives: Cell-based therapies have become increasingly important in the treatment of cancers and inflammatory diseases; however, therapies utilizing monocyte–macrophage lineage cells remain relatively underexplored. Non-invasive cell tracking allows a better understanding of the fate of such cells, which is essential for leveraging their therapeutic potential. Here, we employed a Zirconium-89 (89Zr)-oxine cell labeling method to compare the trafficking of monocytes and macrophages in vivo. Methods: Mouse bone marrow-derived monocytes and macrophages were each labeled with 89Zr-oxine and evaluated for their viability, radioactivity retention, chemotaxis, and phagocytic function in vitro. Labeled cells were intravenously administered to healthy mice and to murine models of granuloma and syngeneic tumors. Cell migration was monitored using microPET/CT, while cell recruitment to the lesions was further assessed via ex vivo biodistribution and flow cytometry. Results: Labeled cells exhibited similar survival and proliferation to unlabeled cells for up to 7 days in culture. While both maintained phagocytic function, monocytes showed higher CCL2-driven chemotaxis compared to macrophages. 89Zr-oxine PET revealed initial cell accumulation in the lungs, followed by their homing to the liver and spleen within 2–24 h, persisting through the 5-day observation period. Notably, monocytes trafficked to the liver and spleen more rapidly than macrophages. In both inflammation and cancer models, monocytes demonstrated higher accumulation at the lesion sites compared to macrophages. Conclusions: This study demonstrates the usefulness of 89Zr-oxine PET in tracking monocyte–macrophage lineage cells, highlighting their distinct migration patterns and providing insights that could advance monocyte-centered cell therapies.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (28)

Satoru Kikuchi

Assistant Professor

Okayama Daigaku

JAPAN
View details

William A. Hall

-

UNITED STATES
View details

Sho Koyasu

助教 / Assistant Professor

Kyoto University

JAPAN
View details

Charles Simone

Professor and Chief Medical Officer

New York Proton Center

UNITED STATES
View details

Hisataka Kobayashi

Chief Scientist/ Senoir Investigator

National Cancer Institute

UNITED STATES
View details

Bradford Wood

Adjunct Professor

University of Maryland

UNITED STATES
View details

Freddy E Escorcia

Investigator, Lasker Clinical Research Scholar, Distinguished Scholar | Head, Laboratory of Molecular Radiotherapy

National Cancer Institute

UNITED STATES
View details

Deborah Citrin

National Cancer Institute

UNITED STATES
View details

Hiroshi Tazawa

Associate Professor

Okayama University Hospital

JAPAN
View details

Adam Sowalsky

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Hiroshi Fukushima

Assistant Professor

Institute of Science Tokyo

JAPAN
View details

Raisa Glabman

Fred Hutch Cancer Center

UNITED STATES
View details

Mitchell Ho

National Cancer Institute

UNITED STATES
View details

Hiroaki Wakiyama

Kyushu University Hospital

JAPAN
View details

Orit Jacobson

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Joon-Yong Chung

National Cancer Institute

UNITED STATES
View details

Amy Kathleen LeBlanc

Director and Senior Scientist

National Cancer Institute

UNITED STATES
View details

Aki Furusawa

National Cancer Institute

UNITED STATES
View details

Toshiaki Ohara

Okayama University

JAPAN
View details

Peter Pinto

Principal Investigator, Chief Prostate Cancer Section

National Cancer Institute

UNITED STATES
View details

Hajime Kashima

Okayama University Hospital

JAPAN
View details

Toshiyoshi Fujiwara

-

JAPAN
View details

Yutaka Kurebayashi

Assistant Professor

Keio University School of Medicine

JAPAN
View details

Palak Patel

Assistant Professor

SUNY Upstate Medical University

UNITED STATES
View details

Melvin Chua

Professor (with Tenure)

Duke-NUS Medical School

SINGAPORE
View details

Radka Stoyanova

Professor and Director of Imaging and Biomarkers

University of Miami

UNITED STATES
View details

Ryuhei Okada

Assistant professor

Tokyo Medical and Dental University

JAPAN
View details

Nathan Lay

Staff Scientist

National Institutes of Health

UNITED STATES
View details